ClinicalTrials.gov
public full text
Public Domain
Tocilizumab Versus Baricitinib in Patients With Severe COVID-19
The aim of this study is to investigate whether baricitinib is non-inferior to tocilizumab in severe COVID-19.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Tocilizumab in Coronavirus-19 Positive Patients#841197
- Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19#1430602
- Tocilizumab for Painful Chronic Pancreatitis#872537
- Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia#860283
- A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With Tocilizumab (RoActemra/Actemra)#1372042
Record · ID 1477947
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive